DXVX announced on the 2nd that it has invited Professor Namjun Cho, founder of Luca AI Cell and a world-renowned expert in biomaterials and infectious disease medicine, as an advisor to DXVX's Americas Business Division.
Last year, DXVX established the Americas Business Division to strengthen research and development collaboration and expand its CRO business targeting the US and global markets. With the recruitment of Professor Namjun Cho, DXVX is expected to rapidly secure global-level new drug research and development capabilities.
Dr. Namjun Cho is a chaired professor in the Department of Materials Science and Engineering at Nanyang Technological University (NTU) in Singapore. He also serves as the project leader of the Stanford School of Medicine's "Antiviral Drug Discovery Centers for Pathogens of Pandemic" center, funded by the US National Institute of Allergy and Infectious Diseases (NIAID). He has led various research areas ranging from infectious disease medicine and antiviral peptide technology to the development of environmentally friendly plastic alternatives.
Luca AI Cell is a bio-venture company founded by Professor Namjun Cho in 2020. It operates a new drug development platform based on universal antiviral peptide therapeutics and artificial cell membrane core technology. In addition to new drug development utilizing lipid nanoparticle (LNP) manufacturing technology, it is also developing applied products such as health functional foods and cosmetics.
DXVX expects that through collaboration with Luca AI Cell, it will be able to significantly enhance its infectious disease response capabilities.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
